cagrisema cagrilintide semaglutide phase 3 obesity drug: what the data shows Novo Nordisk shares plunge after
Novo Nordisk shares plunge after CagriSema obesity drug trial disappoints Reuters News CagriSema's clinical acceleration of weight loss in China Cagrilintidesemaglutide (CagriSema) as an add on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double blind, placebo controlled, multicentre, phase 3 study The Lancet Coadministered Cagrilintide and Semaglutide, in Adults with Overweight or Obesity. June 22,, 2025. DOI: 10.1056 NEJMoa2502081, CagrilintideSemaglutide in Adults with, Overweight or Obesity and Type 2 CagriSema for Obesity Info for Participants Phase Phase 3 Clinical Trial 2026 Power Power
Pay in 4 interest-free payments of $7.01 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13


01022-6/asset/3f55ea20-b36b-4e11-88e9-940a60e8677e/main.assets/gr2_lrg.jpg)